6 assets in Digestive System Neuroendocrine Tumor, Grade 1/2

Therapeutic assets addressing Digestive System Neuroendocrine Tumor, Grade 1/2, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Digestive System Neuroendocrine Tumor, Grade 1/2	National Cancer Institute (NCI)	P3	BB (70)
Oxodotreotide Digestive System Neuroendocrine Tumor, Grade 1/2	Vanderbilt-Ingram Cancer Center	P4	BB (69)
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Digestive System Neuroendocrine Tumor, Grade 1/2	National Cancer Institute (NCI)	P3	BB (68)
Interferon Alfa-2B Digestive System Neuroendocrine Tumor, Grade 1/2	National Cancer Institute (NCI)	P3	B (59)
Abemaciclib Digestive System Neuroendocrine Tumor, Grade 1/2	University of Washington	P2	CCC (53)
Cabozantinib Digestive System Neuroendocrine Tumor, Grade 1/2	National Cancer Institute (NCI)	P3	NR ()